Department of Chemistry "Ugo Schiff", University of Florence, 50019 Sesto Fiorentino, Italy.
Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Int J Mol Sci. 2022 Nov 1;23(21):13302. doi: 10.3390/ijms232113302.
Ovarian cancer recurrence is frequent and associated with chemoresistance, leading to extremely poor prognosis. Herein, we explored the potential anti-cancer effect of a series of highly charged Ru(II)-polypyridyl complexes as photosensitizers in photodynamic therapy (PDT), which were able to efficiently sensitize the formation of singlet oxygen upon irradiation ( and ) and to produce reactive oxygen species (ROS) in their corresponding dinuclear metal complexes with the Fenton active Cu(II) ion/s ([Cu] and [Cu]). Their cytotoxic and anti-tumor effects were evaluated on human ovarian cancer A2780 cells both in the absence or presence of photoirradiation, respectively. All the compounds tested were well tolerated under dark conditions, whereas they switched to exert anti-tumor activity following photoirradiation. The specific effect was mediated by the onset of programed cell death, but only in the case of and was preceded by the loss of mitochondrial membrane potential soon after photoactivation and ROS production, thus supporting the occurrence of apoptosis via photochemical reactions. Thus, Ru(II)-polypyridyl-based photosensitizers represent challenging tools to be further investigated in the identification of new therapeutic approaches to overcome the innate chemoresistance to platinum derivatives of some ovarian epithelial cancers and to find innovative drugs for recurrent ovarian cancer.
卵巢癌复发频繁且与化疗耐药相关,导致预后极差。在此,我们研究了一系列高电荷 Ru(II)-多吡啶配合物作为光敏剂在光动力疗法 (PDT) 中的潜在抗癌作用,这些配合物在光照下(和)能有效地敏化单线态氧的形成,并在其相应的双核金属配合物中产生活性氧物种 (ROS),与 Fenton 活性 Cu(II)离子/s([Cu] 和 [Cu])。我们分别在无光照和有光照的情况下,评估了这些化合物对人卵巢癌细胞 A2780 的细胞毒性和抗肿瘤作用。所有测试的化合物在黑暗条件下都能很好地耐受,而在光照后则转变为发挥抗肿瘤活性。这种特异性作用是通过程序性细胞死亡的发生介导的,但只有在和的情况下,在光激活和 ROS 产生后不久,线粒体膜电位就会丧失,从而支持通过光化学反应发生细胞凋亡。因此,基于 Ru(II)-多吡啶的光敏剂代表了具有挑战性的工具,可以进一步研究,以确定克服某些卵巢上皮癌对铂衍生物的固有化疗耐药性的新治疗方法,并寻找复发性卵巢癌的创新药物。